Syndeio Biosciences (Series A)
Funding Details
- Awarder
- RSS - feeds.feedburner.com
- Date Award
- June 06, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $90,000,000
Company Info
- Traction
- Over $90 million raised to date from leading life science investors.
- Organizations Involved
- AbbVie, Lilly
- Company Description
- Syndeio Biosciences is pioneering precision neurotherapeutics focused on repairing and enhancing synaptic function in central nervous system (CNS) diseases. The company's clinical-stage pipeline and proprietary R&D platform are built on cutting-edge discoveries in synapse biology and translational biomarkers, with a mission to transform treatment for patients suffering from major depressive disorder (MDD), Alzheimer's disease, schizophrenia, and other synaptopathies.
- Market
- Neurotherapeutics
- Location
- Indianapolis, Indiana, United States
- Coinvestors
- Catalio Capital Management, Innoviva, Tenmile, Luson Bioventures, Palo Santo